Under the terms of the agreement, Animas will contribute up to $750,000 to DexCom to offset certain development, clinical and regulatory expenses. The agreement is non-exclusive and does not impact either party’s existing third party development agreements. DexCom anticipates the integrated system will be available to patients in 2009 or early 2010.
The new product will be based on Animas’s advanced pump technology and DexCom’s SEVEN continuous glucose monitoring system. The new technology will enable the Animas pump to receive glucose readings and display this information on the pump’s color screen.
Terrance Gregg, president and CEO of DexCom, said: “We expect future innovations will come from both companies – maximizing choices in glucose monitoring and insulin delivery methods.”